Merck’s Keytruda (pembrolizumab) has been fast-tracked to NHS patients under the U.K.’s new Early Access to Medicines Scheme (EMAS). The drug is the first to be accepted through the initiative, making Keytruda available in the U.K. despite not having an approved Marketing Authorization Application (MAA) by the European Medicines Agency …